Cell and Gene Therapy Supply Chain/Logistics Market Report 2024: Size, Share, Growth, Forecast 2033

"The new report published by The Business Research Company, titled Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the cell and gene therapy supply chain/logistics market size has grown rapidly in recent years. It will grow from $1.25 billion in 2023 to $1.4 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The cell and gene therapy supply chain/logistics market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12631&type=smp

The Surging Demand For Cell And Gene Therapies Reshapes Supply Chain And Logistics
The increasing need for cell and gene therapies is driving the cell and gene therapy supply chain/logistics market. Cell and gene therapies are advanced medical treatments that modify cells or genes to treat diseases, offering potential breakthroughs for untreatable conditions. These cell and gene therapies need to be stored at the proper temperature and storage conditions, which can be achieved using supply chain and logistics services, which help from sourcing to distributing and storing these cell and gene therapies. For instance, in February 2022, according to Cell & Gene, a US-based online resource for research scholars, the private investment in cell and gene therapy in 2021 was $68 billion. Moreover, the number of approved cell and gene therapies experienced a 10% growth in 2021. Therefore, the increasing need for cell and gene therapies drives the cell and gene therapy supply chain/logistics market forward.

Advancements In Technology Propel Cell And Gene Therapy Logistics
Modern technology platforms are a key trend gaining popularity in the cell and gene therapy supply chain/logistics markets. Major companies operating in the market are developing modern technology platforms for cell and gene therapies to sustain their position in the market. For instance, in April 2023, AmerisourceBergen Corporation., a US-based healthcare company specializing in cell and gene therapy supply chain logistics, launched the Cell and Gene Therapy (CGT) Integration Hub. The Cell and Gene Therapy (CGT) Integration Hub is powered by AmerisourceBergen's innovative customer relationship management (CRM) system. It can be integrated into the biopharma platform to facilitate better monitoring of the development and delivery of cell and gene therapies.

The cell and gene therapy supply chain/logistics market covered in this report is segmented -
1) By Type Of Software Solution: Cell Orchestration Platform, Enterprise Manufacturing System, Inventory Management System, Laboratory Information Management System, Logistics Management System, Patient Management System, Quality Management System, Tracking And Tracing System
2) By Mode Of Deployment: Cloud-Based Solution, On-Premises Solution
3) By Component: Cryogenic Shippers, Cryogenic Storage Freezers, Ultra-Low Freezers, Cold Chain Management Systems, Shipment, Storage Medium, Cryogenic Packout Kits, Other Components
4) By Application Area: Donor Eligibility Assessment, Sample Collection, Manufacturing, Logistics, Patient Verification, Treatment Follow-Up
5) By End User: Biobank, Cell Therapy Lab, Hospital, Research Institute, Commercial Organization

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12631&type=discount

Major companies operating in the cell and gene therapy supply chain/logistics market report are AmerisourceBergen Corporation, United Parcel Service, Thermo Fisher Scientific Inc., Avantor Sciences, Lonza Group AG, Arvato Group, Catalent Inc., Charles River Laboratories International, Parexel International Corporation, Cytiva, Almac Group, World Courier, Sharp Packaging Services, PCI Pharma Services, Cryoport Inc., Brooks Life Sciences, BioLife Solutions Inc., Biocair Inc., QuickSTAT, Clarkston Consulting Inc., Central Pharma, TrakCel limited, MAK-SYSTEM International Group, Hypertrust Patient Data Care GmbH, Atelerix Ltd., Polar Express Transportation, Be The Match BioTherapies Inc., Yourway Biopharma Services Company, Azenta Life Sciences Inc., Biostor Ltd.

Contents of the report:
1. Executive Summary
2. Cell And Gene Therapy Supply Chain/Logistics Market Report Structure
3. Cell And Gene Therapy Supply Chain/Logistics Market Trends And Strategies
4. Cell And Gene Therapy Supply Chain/Logistics Market - Macro Economic Scenario
5. Cell And Gene Therapy Supply Chain/Logistics Market Size And Growth
…..
27. Cell And Gene Therapy Supply Chain/Logistics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.